Stock Scorer

QuidelOrtho Corp (QDEL) · Peers

QuidelOrtho against the 15 other companies here in its SEC industry, In Vitro & In Vivo Diagnostic Substances. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 16, highest first.

Measure by measure

MeasureQDELPeer medianRank
Market value $885.31M median $136.69M 6 of 16
Forward P/E 16.7× median 37.8× 4 of 4
P/S 0.3× median 5.1× 16 of 16
FCF yield -23.9% median -8.1% 10 of 15
Gross margin 27.6% median 55.5% 11 of 12
Operating margin -30.8% median -12.2% 7 of 12
Net margin -39.2% median -14.0% 8 of 12
ROIC -13.8% median -11.0% 6 of 11
ROE -59.1% median -26.8% 10 of 12
Revenue growth (4y, yearly) 12.6% median 8.7% 7 of 15
Current ratio 1.4× median 3.5× 12 of 15
Stock pay / revenue 1.7% median 5.3% 11 of 15
Share count change 0.9% median 9.4% 12 of 15

Green where QuidelOrtho is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.

The peers, largest first

CompanyMarket valueP/EROICScore
QDELQuidelOrtho Corp $885.31M P/E – -13.8% 3.2
IDXXIDEXX Laboratories Inc $44.15B P/E 38.7× 57.2% 6.0
LNTHLantheus Holdings, Inc. $6.51B P/E 23.6× 18.5% 6.2
NEOGNeogen Corp $2.58B P/E – -0.6% 4.2
CLDXCelldex Therapeutics, Inc. $2.16B P/E – – 2.9
NTLAIntellia Therapeutics, Inc. $1.60B P/E – -115.4% 3.6
MYGNMyriad Genetics Inc $380.69M P/E – -25.2% 4.7
TKNOAlpha Teknova, Inc. $380.11M P/E – -21.4% 4.1
NNNNAnbio Biotechnology $136.69M P/E 21.3× 25.0% 5.6
IMDXInsight Molecular Diagnostics Inc. $98.50M P/E – – 3.0
ICCCImmucell Corp $97.63M P/E 25.9× 9.8% 5.9
AWHLAspira Women's Health Inc. $10.73M P/E – – 4.0
BMRABiomerica Inc $8.49M P/E – -213.5% 3.4
CDIOCardio Diagnostics Holdings, Inc. $5.00M P/E – -68.7% 3.4
QCLSQ/C Technologies, Inc. $4.41M P/E – – 7.5
VNRXVolitionrx Ltd $2.46M P/E – – 4.1

The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.